Abstract
Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have